Pancreatic Cancer Research

ResearcherGarvan Institute of Medical ResearchNo recent work listed

Christopher James Scarlett

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4140-7785; OpenAlex author ID A5063657901. Sources: OpenAlex.

Their work

Papers
26 (first author 2, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2011: 3 papers · 2012: 2 papers · 2013: none · 2014: 4 papers · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 5 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 26

  1. Novel piperazine-1,2,3-triazole leads for the potential treatment of pancreatic cancer. Co-author DOI 10.1039/d2md00289b↗
  2. 3,5-Bis(trifluoromethyl)phenylsulfonamides, a novel pancreatic cancer active lead. Investigation of the terminal aromatic moiety. Co-author DOI 10.1016/j.bmcl.2022.128591↗
  3. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  4. In vitro anti-pancreatic cancer activity of HPLC-derived fractions from Helicteres hirsuta Lour. stem. Last author DOI 10.1007/s11033-019-05180-0↗
  5. Elaeocarpus reticulatus fruit extracts reduce viability and induce apoptosis in pancreatic cancer cells in vitro. Last author DOI 10.1007/s11033-020-05307-8↗
  6. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  7. Small molecule inhibitors in pancreatic cancer. Co-author DOI 10.1039/c9md00447e↗
  8. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  9. The Bispidinone Derivative 3,7-Bis-[2-(S)-amino-3-(1H-indol-3-yl)-propionyl]-1,5-diphenyl-3,7-diazabicyclo[3.3.1]nonan-9-one Dihydrochloride Induces an Apoptos… Last author DOI 10.3390/molecules24030524↗
  10. Cytotoxic activity of extracts and fractions from Paramignya trimera root and Phyllanthus amarus against pancreatic cancer cell lines. First author DOI 10.4103/jcrt.jcrt_85_18↗
  11. An Array of Bioactive Compounds From Australian Eucalypts and Their Relevance in Pancreatic Cancer Therapeutics. Last author DOI 10.1097/mpa.0000000000001074↗
  12. The Olive Biophenols Oleuropein and Hydroxytyrosol Selectively Reduce Proliferation, Influence the Cell Cycle, and Induce Apoptosis in Pancreatic Cancer Cells. Last author DOI 10.3390/ijms19071937↗
  13. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  14. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  15. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  16. Phytochemical properties and anti-proliferative activity of Olea europaea L. leaf extracts against pancreatic cancer cells. Last author DOI 10.3390/molecules200712992↗
  17. The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa… Last author DOI 10.3892/ijo.2015.2894↗
  18. Fruit-derived phenolic compounds and pancreatic cancer: perspectives from Australian native fruits. Last author DOI 10.1016/j.jep.2013.12.023↗
  19. A historical perspective of pancreatic cancer mouse models. First author DOI 10.1016/j.semcdb.2014.03.025↗
  20. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Co-author DOI 10.1038/bjc.2013.722↗
  21. Targeting mTOR dependency in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2013-306202↗
  22. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Co-author DOI 10.1038/nature11547↗
  23. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Co-author DOI 10.1093/annonc/mdr561↗
  24. Precursor lesions in pancreatic cancer: morphological and molecular pathology. Co-author DOI 10.1097/pat.0b013e3283445e3a↗
  25. Recruitment and activation of pancreatic stellate cells from the bone marrow in pancreatic cancer: a model of tumor-host interaction. Co-author DOI 10.1371/journal.pone.0026088↗
  26. Retinoid signaling in pancreatic cancer, injury and regeneration. Co-author DOI 10.1371/journal.pone.0029075↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adam McCluskey · 4 shared papers, 2019–2023 · strength 0.60
  2. Ju‐Feng Sun · 3 shared papers, 2020–2023 · strength 0.51
  3. Quan V. Vuong · 5 shared papers, 2014–2020 · strength 0.50
  4. Chloé Goldsmith · 4 shared papers, 2014–2023 · strength 0.38
  5. Hong Ngoc Thuy Pham · 2 shared papers, 2020–2023 · strength 0.35
  6. Emily K. Colvin · 7 shared papers, 2011–2020 · strength 0.31
  7. Andrew Victor Biankin · 8 shared papers, 2011–2020 · strength 0.29
  8. David Kuang-Fu Chang · 7 shared papers, 2011–2020 · strength 0.25
  9. James G. Kench · 6 shared papers, 2011–2020 · strength 0.21
  10. Van Tang Nguyen · 1 shared paper, 2019 · strength 0.20
  11. Marina Pajic · 5 shared papers, 2011–2020 · strength 0.20
  12. Jeremy L. Humphris · 3 shared papers, 2012–2020 · strength 0.13
  13. Jaswinder Singh Samra · 3 shared papers, 2012–2020 · strength 0.13
  14. Amber L. Johns · 3 shared papers, 2012–2020 · strength 0.13
  15. Venessa T. Chin · 3 shared papers, 2012–2020 · strength 0.13
  16. Lorraine A. Chantrill · 3 shared papers, 2012–2020 · strength 0.13
  17. Anthony James Gill · 3 shared papers, 2012–2020 · strength 0.13
  18. Adnan M. Nagrial · 3 shared papers, 2012–2020 · strength 0.13
  19. Alexandria Turner · 1 shared paper, 2020 · strength 0.13
  20. Deep Jyoti Bhuyan · 1 shared paper, 2018 · strength 0.11
  21. Angela S. Y. Chou · 2 shared papers, 2014–2020 · strength 0.11
  22. Nigel Balfour Jamieson · 2 shared papers, 2014–2020 · strength 0.10
  23. Colin J. McKay · 2 shared papers, 2014–2020 · strength 0.10
  24. C. Ross Carter · 2 shared papers, 2014–2020 · strength 0.10
  25. Neil Donald Merrett · 2 shared papers, 2012–2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.